BETonMACE: Negative Trial, but 'Cautious Optimism' on Apabetalone
Medscape,
PHILADELPHIA — The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular…
BETonMACE: Negative Trial, but 'Cautious Optimism' on Apabetalone
Medscape,
PHILADELPHIA — The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular…
Epigenetischer Therapieansatz zur Prävention nach ACS scheitert knapp
Medscape,
Philadelphia – Der BET-Inhibitor Apabetalon erreichte in der Phase-3-Studie BETonMACE den primären Endpunkt nicht.
Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE
TCTMD,
The phase III trial failed to meet its primary endpoint, but some hold out hope for this new drug class in other populations.
Resverlogix To Release Phase 3 Clinical Trial Data On A First-In-Class BET Bromodomain Inhibitor
Seeking Alpha,
Resverlogix is to release topline Phase 3 results from the BETonMACE phase 3 clinical trial on September 30.